{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-075734","form_type":"8-K","ticker":"SLNO","cik":"0001484565","company_name":"SOLENO THERAPEUTICS INC","filed_at":"2023-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.192661+00:00","generated_at":"2026-06-17T22:11:52.061631+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Soleno Therapeutics Reports Q4 and Full-Year 2022 Financial Results, Provides Clinical Update","bullets":["Enrollment nearing completion in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome; top-line data expected Q3 2023.","Securities purchase agreement with Nantahala Capital, Abingworth, and Vivo Capital for up to $60 million in gross proceeds.","Cash and cash equivalents of $14.6 million as of December 31, 2022.","Net loss of $5.5 million for Q4 2022, compared to $2.8 million in Q4 2021.","R&D expenses were $3.8 million for Q4 2022, compared to $3.7 million in Q4 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-075734","json":"https://secwatch.observer/filing/0001193125-23-075734.json","markdown":"https://secwatch.observer/filing/0001193125-23-075734.md","text":"https://secwatch.observer/filing/0001193125-23-075734.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/d380040d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T22:11:52.061631+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"41f1e568135c20bd96d269883db38ea4287be9f8","claim":"SOLENO THERAPEUTICS INC reported the year ended December 31, 2022 results: net income approximately $24.1 million, EPS $2.87 per basic and diluted share.","evidence_excerpt":"Net loss for the year ended December 31, 2022, was approximately $24.1 million, or $2.87 per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2022"},{"label":"Net income","value":"approximately $24.1 million"},{"label":"EPS","value":"$2.87 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"5a06a764f45ca451e7b61bdcd56e83e95eb40483","claim":"SOLENO THERAPEUTICS INC reported the fourth quarter ended December 31, 2022 results: net income approximately $5.5 million, EPS $0.58 per basic and diluted share.","evidence_excerpt":"Net loss was approximately $5.5 million, or $0.58 per basic and diluted share, for the quarter ended December 31, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1484565/000119312523075734/0001193125-23-075734-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Net income","value":"approximately $5.5 million"},{"label":"EPS","value":"$0.58 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}